EZH2在原发性肝癌发展中的作用及临床病理意义

Role of EZH2 in development of primary hepatocellular carcinoma and its clinicopathological significance

目的探讨EZH2在原发性肝细胞癌(HCC)以及癌旁组织中表达的差异及其临床病理意义。方法收集2011年6月至2012年6月第四军医大学附属医院HCC患者手术切除标本46例,免疫组化采用链霉素抗生物素蛋白-过氧化物酶连结法(SP法)检测HCC组织及癌旁组织中EZH2蛋白表达情况;分析其与临床病理因素的关系。结果 HCC组织中EZH2蛋白表达水平明显高于相应癌旁组织(P<0.05),其在HCC中表达率较高[45.7%(21/46)];在癌旁组织中表达率低[4.3%(2/46)]。EZH2蛋白表达水平与有无癌栓、肝硬化及肝脂肪变性等临床病理因素无明显相关性。结论 EZH2在HCC中呈高表达,提示EZH2的异常表达与HCC的发生和发展有关。

Objective To investigate the difference of EZH2 expression between primary hepatocellular carcinoma （HCC） and pericarcinous tissues and its clinieopathologieal significance. Methods 46 cases of HCC in the Affiliated Hospital of Fourth Military Medical Univrsity from June 2011 to June 2012 were collected, hnmunohistochemistry was used to detect the expression of EZH2 in HCC and the pericarcinous tissues, and its relation with clinicopathological factors was analyzed. Results The level of EZH2 expression in HCC was significantly higher than that in pericarcinous tissues （P〈0.05）, the positive rate of EZH2 expression in HCC[45.7% （21/46）] was higher, which in the adjacent tissues[4.3% （2/46）] was lower. The expression level of EZH2 had no correlation with the clinincopathological factors such as cancer embolus,cirrhosis and fatty liver（P〈0.05）. Conclusion EZH2 shows high expression in HCC, suggesting that the abnormal expression of EZH2 is related with the development and progress of HCC.